Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs

Mast cell tumours (MCT) are common skin tumours in dogs. If complete surgical removal of the tumours is not possible, then another therapy is needed. In the current study we tested the therapeutic effect of intratumoural injection of interleukin-2 (IL-2). Seven dogs had non-resectable cutaneous MCT....

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2013-01, Vol.33 (1), p.161-165
Main Authors: Ziekman, Paul G P M, Otter, Willem D E N, Tan, Jurgen F V, Teske, Erik, Kirpensteijn, Jolle, Koten, Jan-Willem, Jacobs, John J L
Format: Article
Language:English
Subjects:
Animals
Dogs
Female
Genetic Therapy
Humans
Interleukin 2
Interleukin-2 - therapeutic use
Male
Mast cells
Mast-Cell Sarcoma - genetics
Mast-Cell Sarcoma - pathology
Mast-Cell Sarcoma - therapy
Mast-Cell Sarcoma - veterinary
mastocytoma
Pilot Projects
Side effects
Skin
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mast cell tumours (MCT) are common skin tumours in dogs. If complete surgical removal of the tumours is not possible, then another therapy is needed. In the current study we tested the therapeutic effect of intratumoural injection of interleukin-2 (IL-2). Seven dogs had non-resectable cutaneous MCT. The tumours were injected with 4.5×10(6) IU IL-2. The early clinical effects in the seven dogs with cutaneous MCT were: complete regression (CR) in two dogs; partial regression (PR) in four, and stable disease (SD) in one dog. The final clinical effects were CR in three dogs, PR in two dogs, and PD in two dogs. This pilot study shows that intratumoural IL-2 application can exert an anti-MCT effect. A larger study would be required to precisely establish the magnitude of the therapeutic effect against MCT. A single application of IL-2 in cases of non-resectable MCT has no observable side-effects.
ISSN:0250-7005
1791-7530